Brepocitinib (TYK2/JAK1 Inhibitor — Dermatomyositis)

How it works

It inhibits both TYK2 and JAK1, dampening signalling of multiple pro-inflammatory cytokines that contribute to immune-mediated tissue inflammation.

Prescribing in practice

• As a JAK-pathway inhibitor it would be expected to carry class risks of serious infection, and screening for infection including tuberculosis is appropriate before use.
• It is an investigational specialist agent used within trials or expert settings rather than in routine UK practice.
• By analogy with the JAK inhibitor class, attention to laboratory parameters, thromboembolic risk and vaccination status is prudent; refer to current prescribing references and trial protocols.

Monitoring

Monitor for infection and relevant laboratory parameters in line with JAK-pathway inhibitor class precautions and the governing study protocol.

Counselling the patient

• Report any signs of infection promptly.
• Tell the team about any planned vaccinations, as live vaccines are generally avoided with this drug class.
• Take the medicine exactly as directed within the trial or specialist plan.

Evidence & guidelines

Evidence is from clinical trials in immune-mediated disease; it is not an established licensed therapy and class effects are inferred from the broader TYK2/JAK inhibitor literature.